Trevi Therapeutics, Inc.
TRVI
$13.35
$0.050.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.74M | 13.77M | 12.71M | 12.15M | 11.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.35M | 51.52M | 51.09M | 51.53M | 48.22M |
| Operating Income | -51.35M | -51.52M | -51.09M | -51.53M | -48.22M |
| Income Before Tax | -45.89M | -47.35M | -47.38M | -47.94M | -44.35M |
| Income Tax Expenses | -31.00K | -47.00K | -34.00K | -31.00K | -29.00K |
| Earnings from Continuing Operations | -45.86 | -47.30 | -47.35 | -47.91 | -44.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.86M | -47.30M | -47.35M | -47.91M | -44.32M |
| EBIT | -51.35M | -51.52M | -51.09M | -51.53M | -48.22M |
| EBITDA | -51.20M | -51.37M | -50.94M | -51.38M | -48.07M |
| EPS Basic | -0.37 | -0.42 | -0.45 | -0.47 | -0.44 |
| Normalized Basic EPS | -0.23 | -0.26 | -0.28 | -0.29 | -0.28 |
| EPS Diluted | -0.37 | -0.42 | -0.45 | -0.47 | -0.44 |
| Normalized Diluted EPS | -0.23 | -0.26 | -0.28 | -0.29 | -0.28 |
| Average Basic Shares Outstanding | 499.08M | 455.25M | 425.94M | 407.85M | 401.33M |
| Average Diluted Shares Outstanding | 499.08M | 455.25M | 425.94M | 407.85M | 401.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |